Future investigations should utilize patient-derived xenografts and organoid models to elucidate the mechanisms by which LRRC8A contributes to drug resistance across diverse genetic backgrounds, thereby establishing a foundation for novel therapeutic interventions and improved chemotherapeutic efficacy, ultimately enhancing clinical outcomes for cancer patients (Fig. 2). The gene discussed is LRRC8A; the disease is cancer.